Ara
Toplam kayıt 1, listelenen: 1-1
Real-life analysis of immunotherapy as the second or later lines treatment in patients with metastatic non-small cell lung cancer
(Ankara Society of Hematology and Oncology, 2021)
Background: Immunotherapy agents such as atezolizumab and nivolumab are appropriate option for non-small cell lung cancer (NSCLC) accounts in the absence of driver mutation, regardless of PDL-1 expression in second and ...